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http://www.ojrd.com/content/8/1/108RESEARCH Open AccessA synonymous change, p.Gly16Gly in MECP2
Exon 1, causes a cryptic splice event in a Rett
syndrome patient
Taimoor I Sheikh1,2, Kirti Mittal1, Mary J Willis3 and John B Vincent1,2,4*Abstract
Background: Mutations in MECP2 are the main cause of Rett Syndrome. To date, no pathogenic synonymous
MECP2 mutation has yet been identified. Here, we investigated a de novo synonymous variant c.48C>T (p.Gly16Gly)
identified in a girl presenting with a typical RTT phenotype.
Methods: In silico analyses to predict the effects of sequence variation on mRNA splicing were employed, followed by
sequencing and quantification of lymphocyte mRNAs from the subject for splice variants MECP2_E1 and MECP2_E2.
Results: Analysis of mRNA confirmed predictions that this synonymous mutation activates a splice-donor site at an early
position in exon 1, leading to a deletion (r.[=, 48_63del]), codon frameshift and premature stop codon (p.Glu17Lysfs*16) for
MECP2_E1. For MECP2_E2, the same premature splice site is used, but as this is located in the 5′untranslated region, no
effect on the amino acid sequence is predicted. Quantitative analysis that specifically measured this cryptic splice variant
also revealed a significant decrease in the quantity of the correct MECP2_E1 transcript, which indicates that this is the
etiologically significant mutation in this patient.
Conclusion: These findings suggest that synonymous variants of MECP2 as well as other known disease genes—
and de novo variants in particular— should be re-evaluated for potential effects on splicing.
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Rett syndrome (RTT; MIM#312750) is an X-linked neuro-
logical disorder which leads to gradual slowing of neuro-
development in females. Clinical features and symptoms
may include microcephaly, repetitive hand movement,
scoliosis, constipation, excessive saliva, intellectual dis-
ability (ID), and typically little or no verbal skills.
Methyl-CpG binding protein 2 (MeCP2; MIM 300005)
[1] located at Xq28, was identified as the gene respon-
sible for RTT [2]. Initially, MeCP2 was identified due to
its selective binding (via a methyl-CpG binding domain
(MBD)) to DNA sequences that are methylated at cytosine
in the dinucleotide CpG [3]. Subsequently, other highly
conserved and functionally relevant domains, namely
the transcriptional repression domain (TRD) and nuclear* Correspondence: john.vincent@camh.ca
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reproduction in any medium, provided the orlocalization signal (NLS) were also identified [4,5] (Figure 1).
Other functionally less well characterized domains include
a C-terminal domain (CTD), which putatively binds to his-
tone [6]. The MBD of MeCP2 does not only recognize
methylated DNA, but can also bind unmethylated DNA.
Additional unmethylated DNA binding sites are present
between the MBD and TRD, and are known as the inter-
vening domain (ID) (Figure 1) [7].
The canonical version of MECP2 gene consists of 4
coding exons. The translation START site is in exon 2,
and exon 1 and most of exon 2 are within the 5′untrans-
lated region (UTR). However, a splice variant of MECP2
was discovered later, namely MECP2_E1, in which exon 2
is spliced out and translation is initiated from a START
codon in exon 1, thus resulting in a slightly larger pro-
tein with a different N-terminal [9,10] (Figure 1). The two
isoforms are identical for the remainder of the protein,
and both contain the MBD and TRD (Figure 1). Several
studies suggested that MeCP2_E1 is the predominantLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 MeCP2 Domain Structure: NTD: N-terminal domain, MBD: methyl-CpG DNA binding domain, ID: intervening domain,
TRD: transcription repression domain and CTD is C-terminal domain. Domain-wise distribution of amino acids of both isoforms of MECP2
protein. Amino acid counts for each domain of MeCP2_E1 was based on that for a previously described MeCP2_E2 domain structure [8].
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[9,10]. MECP2_E1 is not only transcribed at much
higher levels in the brain than the canonical splice vari-
ant, MECP2_E2, but is also translated more efficiently.
The presence of the upstream open reading frame ap-
pears to inhibit the efficient translation of MeCP2_E2
[10]. The N-terminal region encoded by MECP2_E1 is
highly conserved across all vertebrate groups, and is
identical among many mammalian species [11].
There are currently over 250 known MECP2 gene mu-
tations that cause RTT [12]. Over 80% of patients with
RTT have mutations in exons 3 or 4 of MECP2. The
identification of disease-relevant mutations in exon 1 led
to the likelihood that MeCP2_E1 is the etiologically rele-
vant protein isoform for Rett [9,13,14], later confirmed by
studies of mouse knockouts specific to isoform MeCP2_e2
[15], and has also led to the inclusion of exon 1 in diag-
nostic sequencing for Rett syndrome.
Here, we have identified a novel synonymous mutation
in the coding portion of exon1 of MECP2_E1 at position
c.48C>T. This mutation was initially characterized as a
silent mutation as it changes the 16th codon from GGC
to GGU/T, both of which code for glycine, i.e. p.Gly16Gly.
In silico analysis of this synonymous variant predicts
potential activation of a cryptic mRNA splice donor site
upstream of the exon 1 splice donor site, which could
result in a frameshift in the mRNA during protein transla-
tion and hence may ultimately result in protein truncation
(Figure 2). Here, we present molecular evidence through
analysis of mRNA sequence and mRNA quantization,
confirming the activation of this cryptic splice donor.
Materials and methods
Patient ascertainment/assessment
The proband was ascertained and assessed through the
Clinical Genetics Department at the Naval Medical CenterSan Diego, and recruited into a study of MECP2 based
at the Campbell Family Mental Health Research Institute,
Centre for Addiction & Mental Health, Toronto. Institu-
tional research ethics approval was obtained for this study,
and written consent for the study was given by the pro-
band’s parents. Recruitment of control subjects for mRNA
quantification analysis has been described previously [16].
Bioinformatic analysis
Potential splice sites were predicted using the online
neural network tool at the Berkeley Drosophila Genome
Project (BDGP) (http://www.fruitfly.org/seq_tools/splice.
html), also using Human Splicing Finder (HSF; www.
umd.be/HSF/) and MaxEntScan (genes.mit.edu/burgelab/
maxent/Xmaxentscan_scoreseq.html). ExPASy Swiss insti-
tute of bioinformatics (http://web.expasy.org/translate)
online translate tool was used to identify the potential ef-
fect of this splice site mutation on the reading frame of
the mutated version of protein.
Cell culture and RNA preparation
Total RNA from the patient was extracted from a) lympho-
cytes drawn into Tempus™ tubes (Invitrogen Life Technolo-
gies), following the manufacturer’s protocol for PureLink®
RNA Mini Kit (Invitrogen Life Technologies), and b) from
Epstein-Barr Virus (EBV)-transformed blood cells (lym-
phoblasts), grown in RPMI medium supplemented with
15% Fetal Bovine Serum (FBS) and 1X penicillin strepto-
mycin, with RNA extracted using Trizol method (all from
Invitrogen Life Technologies).
Reverse transcriptase polymerase chain reaction (RT-PCR)
& Sanger Sequencing
RT-PCR analysis targeting the N-terminal coding regions
for MECP2_E1 and MECP2_E2 was performed using sets
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Figure 2 Activation of cryptic splice site at c.48C>T in MECP2 exon 1: A) ideogrammatic representation of the genomic organization of
MECP2, showing the alternative pre-mRNA splicing of wild type (WT) and mutant (Mut (NM_001110792: c.48C>T)) transcripts for both
isoforms, MeCP2_E1 and MeCP2_E2; B) Agarose gel electrophoresis of reverse transcription-PCR product for WT (Lane 2, 140bp) and
Mut (Lane 3, 124 bp) transcripts; C) cDNA sequence chromatograms of WT (left) and Mut (right) MECP2_E1 transcripts. The MECP2 exon
1–3 boundary sequence for the WT mRNA is indicated with a blue arrow, whereas MECP2 exon 1–3 boundary sequence of the Mut mRNA is
indicated with a red arrow. The 16bp sequence that is deleted in the Mut transcript between the cryptic splice junction and correct splice
junction is indicated within the WT sequence using red brackets. D) Illustration of the predicted amino acid sequence of the MeCP2_E1 WT
(green) and Mut (orange). The change of Glu at position 17 into Lys followed by a frameshift and introduction of a stop codon after 16 amino
acids is indicated.
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(See Table 1). First strand cDNA was synthesized using
Superscript III (Invitrogen) from RNA treated with
DNase I (Fermentas). Following RT-PCR amplification
across MECP2 exons 1 to 3, sequencing analysis of the
gel-eluted product (Qiagen) was performed at The Centre
for Applied Genomics (www.tcag.ca) using gene specific
primers (Figure 2).
TA cloning, colony screening and high resolution
gel electrophoresis
Gel-eluted PCR product obtained from the previous step
was cloned into the pDRIVE vector according to the man-
ufacturer’s instruction (Qiagen). Selection of recombinantcolonies was primarily done using α-complementation of
the β-galactosidase gene with isopropyl β-D-1-thiogalacto-
pyranoside (IPTG) supplemented LB agar. Colony-PCR
of individually picked bacterial colonies was carried out
using T7 and SP6 as forward and reverse primers.
PCR-amplification with forward primer 5′-CCGAGCG
GAGGAGGAGGAGG-3′ from exon 1 and reverse pri-
mer 5′-TGCTTGCCCTCTTTCTCTTC-3′ (exon 3)
was followed by 2% high resolution agarose gel electro-
phoresis at 120V for 1 hour. PCR products were seen at
the expected sizes, i.e. 140 bp for the normal transcript
TA clone, and 124 bp for the mutated transcript TA
clone, alongside 50 bp DNA ladder (Fermentas)
(Figure 2).
Table 1 RT-PCR assay details: PCR primer and probe sequences, or TaqMan™ assay ID
Assay specification Assay ID Assay details
Detects Normal MeCP2_E1 transcript only MeCP2_E1 NL Left 5′-CGGAGGAGGAGGAGGA-3′
Right 5′-GGAGGTCCTGGTCTTCTGACTT-3′
Probe 6FAM-5′-AGGAGGAGAGACTGGAA3′
Detects Mutated MeCP2_E1 transcript only MeCP2_E1 Mut Left 5′-GTAAAAGCCGTCCGGAAAAT-3′
Right 5′-TGCTTGCCCTCTTTCTCTTC-3′
Probe 6FAM-5′-AGGAGGAGGGAAGAAA-3′
Detects MeCP2_E2 transcript only MeCP2_E2 TaqMan™ Pre-Designed Gene expression Assay
ID number: Hs00172845
Detects PGK1 transcript only (Endogenous control) PGK1 TaqMan™ Pre-Designed Gene expression Assay
ID number: Hs99999906
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Quantification of mutant and wild type transcripts was
carried out using custom designed TaqMan® qRT-PCR
gene expression assays (Figure 3B), using cDNA from
the proband and three healthy female control individuals.
Applied Biosystems® TaqMan® Universal PCR Master Mix,
with optimal amplification conditions were used for all
assays. All samples were analyzed in triplicate (three
biological replicates) and normalized using phospho-
glycerate kinase 1 gene (PGK1) as an endogenous control.
All assays were designed according to the manufacturer’s
instructions and the Primer Express 3.0 software tool
(Applied Biosystems, Foster City, CA USA).
Data analysis
Quantitative analyses of the data were carried out





















Figure 3 5′ Nuclease Assay: A) Relative fold-change in the gene expre
MECP2_E2 transcripts in RTT individual with c.48C>T substitution, and t
endogenous control PGK1. Fold-change in the gene expression was calculate
indicate standard error of the means. All reactions were done using three bioFoster city USA). Greater than 36 Cycle threshold (Ct)
value (from a total of 40 cycles of amplification) were
considered as undetected [17]. Fold-differences in gene
expression were calculated using the comparative cycle
threshold method (ΔΔ Ct method) [17,18]. Statistical ana-
lysis was performed to calculate standard error of means
(S.E.M) and standard deviations (SD) using Microsoft
Excel tool for descriptive statistics.
Results
The clinical details of the patient are reported here:
Patient 1 information:
The patient is a five-year three-month-old female born of
non-consanguineous parents. She has a younger brother
who is developing normally. Her parents are both healthy,

















ssion of MECP2_E1 normal (NL), MECP2_E1 mutant (MT), and
hree healthy control subjects. All samples were normalized to
d using ΔΔCt method and shown after log transformation. Error bars
logical replicates per sample. B) Subject details. (ND*: Not detected).
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nancy. Birth weight was 50th centile, and head circumfer-
ence, 25th centile. Concerns about her development arose
around nine months of age when her progress seemed to
slow, although without suggestion of regression. She sat at
six months, walked at 18 months, began babbling at nine
months of age but speech never progressed beyond that,
and babbling has mostly disappeared. At two years of age
she began having seizures. Cranial computed tomography
(CT) and magnetic resonance imaging (MRI) at that time
were normal. Electroencephalography (EEG) showed
multifocal sharp waves. She developed multiple seizure
types over time; tonic-clonic, complex partial, absence,
and atonic seizures. Brain MRI was repeated at 4.5 years
to include spectroscopy and was also normal.
In terms of the revised diagnostic criteria for RTT [19],
she meets all four main criteria (loss of acquired purpose-
ful hand skills, loss of acquired spoken language, gait
abnormaility and sterotpical hand movelments) and at
least seven out of 11 of the supportive criteria (breathing
disturbance while awake, bruxism while awake, impaired
sleep pattern, abnormal muscle tone, growth retardation,
diminished response to pain and intense eye communica-
tion (“eye pointing”). Hands and feet were cold, although
not small. Thus she meets criteria for typical or classic
RTT in all except that regression is still ongoing, and a
period of recovery or stabilization has not yet been
established. Thus we have designated her with a diagno-
sis of typical Rett syndrome.
Molecular and bioinformatics analyses:
Metabolic evaluations and karyotyping were normal.
Comparative genomic hybridization identified a 560 Kb
(chr14: 37,627,931-38,187,142; hg19) duplication at 14q21.1
which contains two genes; mirror-image polydactyly gene 1
(MIPOL1) which is associated with mirror image poly-
dactyly, and Forkhead box protein A1 (FOXA1) which
is a transcription factor found to be overexpressed in
some tumor types. This rare gain copy number variant
was also present in the father’s DNA, thus excluding
non-paternity. Molecular evaluations have also included
normal Angelman syndrome methylation analysis, ubiquitin-
protein ligase E3A (UBE3A) sequence analysis, and screen-
ing using a mitochondrial DNA point mutation panel.
MECP2 sequence analysis identified a heterozygous
single nucleotide substitution from C→T in MECP2 exon
1 at nucleotide position 48 of the MECP2_E1 coding se-
quence (c.48C>T). This substitution was not present in
either parent, and is likely to be de novo. The variant
has not been reported in large scale whole exome or
genome sequencing projects (1000 Genomes (phase 1
integrated release) and the NHLBI Exome Sequencing
Project (ESP6500 data release)). The substitution is at
the 3rd (wobble) position of a glycine codon, and doesnot alter the coded amino acid (i.e. a synonymous
change). According to the BDGP splice site prediction,
the donor score for nucleotide positions c.47-48 is altered
from <0.01 (WT) to 0.85 (Mutant; Figure 2A). Analysis
using other algorithms supports this (Additional file 1:
Table S1). The agarose gel electrophoresis of PCR ampli-
fied cDNA shows two bands for the MECP2_E1 transcript
for the affected individual. Upon separation of the
mutated version from the normal transcript by clon-
ing into a TA cloning vector, followed by sequencing
analysis, it was revealed that the transcript resulting
from c.48C>T lacks 16 nucleotides at the 3′end of
exon 1 (r.[=, 48_63del]) (Figure 2B, C), indicating that
c.48C>T results in a premature splicing event, as pre-
dicted. Although it splices with the correct acceptor
site at intron 2/exon 3, due to the 16 nt deletion in
exon 1 it is predicted to result in a frameshift event,
changing glutamic acid (Glu) at position 17 into lysine
(Lys), and leading to a truncated protein with a stop
codon after 16 amino acids (p.Glu17Lysfs*16) (Figure 2D).
Analysis of the effect of c.48C>T on splicing for the
MECP2_E2 splice variant showed similar results, with
the last 16 nt of exon 1 missing, but the correct usage of
the splice acceptor at the intron 1/exon 2 boundary. As
this deletion lies within 5′ untranslated region (UTR), it
is not predicted to affect the 486 amino acid open read-
ing frame of MECP2_E2, however, bioinformatic analysis
shows that it results in an upstream open reading frame
(ORF) 27 amino acids in length. This may putatively re-
duce the efficiency of translation of the full length ORF.
Further, quantification of the mutated and wild type
mRNA transcripts showed a significant difference in the
transcription levels. Approximately two-fold average
decrease in expression of the WT MECP2_E1 transcript
(MECP2_E1 NL) was observed in Patient 1, whereas mu-
tated transcripts (MECP2_E1 MT) were not detected (ND)
in the normal samples. Relative expression of theMECP2_E2
isoform was also quantified. An average of ~1.4-fold in-
crease in the expression of the WT MECP2_E2 transcripts
was observed in Patient 1 (Figure 3A).
No mutant c.48C>T alleles from the patient showing
the correct splicing at the canonical exon 1 splice donor
site were identified in either MECP2_E1 or E2 transcripts,
and all transcripts that did show splicing at the canonical
exon 1 donor site were derived from the WTallele.
Discussion
Synonymous mutations are generally considered as non-
pathogenic, and are not expected to change the protein’s
function. This paradigm has been challenged in recent
years, with evidence that changes in codon usage may
have consequences for the efficiency and speed of trans-
lation, that, in turn, may then affect protein folding and
function [20,21]. In addition, the possible pathogenic
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wobble sites creating aberrant splice sites, is frequently
overlooked, but while there are a number of reports
with evidence for this at missense (non-synonymous)
sites, there are fewer reports of such a mechanism in
human disease involving synonymous changes [22]. To
date, no synonymous mutation in MECP2 has been
proven to be pathogenic.
In this report, we have described the functional conse-
quences of a synonymous mutation in MECP2 exon 1,
c.48C>T in a girl with a typical, albeit relatively mild
form of RTT. This C>T transition changes the codon
GGC into GGT, coding for the same amino acid i.e. gly-
cine (p.Gly16Gly) (Figure 2A). At the transcriptional level
this silent change clearly affects the gene expression by
introducing a premature splice-donor site, resulting in the
removal of 16nt of coding sequence from MECP2_E1
transcripts r.[=, 48_63del], This causes a frameshift,
and premature truncation is predicted after 16 amino
acid residues (KKSQKTSRTNPSSLKR*) (p.Glu17Lysfs*16)
(Figure 2D). The effect of the mutation is similar for splice
variant MECP2_E2, in that the last 16nt of exon 1 are
removed, however, as this lies within the 5′UTR, there is
no predicted effect on the protein. However, as the frame
in the 5′UTR changes with the mutation and 16nt dele-
tion, this may have an effect on the translation efficiency
of MECP2_E2. The number and position of stop codons
upstream to the translation start site remains unchanged,
but while WT MECP2_E2 has no apparent upstream
ORF, the mutant form does have a 27 amino acid up-
stream ORF, which may compete for translational machin-
ery with the correct ORF beginning in exon 2. Thus, while
reduction in MeCP2_E1 protein levels is the most likely
etiologically relevant consequence of the mutation in
Patient 1, we cannot exclude that a reduction in MeCP2_E2
protein levels caused by translational interference is also
contributing to the phenotype.
Reduced MeCP2 expression is likely one of the main
pathogenic mechanisms in RTT [23]. Quantitative analysis
of MECP2_E1 and E2 mRNA for Patient 1 suggest that this
aberrant splice event is specific to the patient, and occurs
in roughly half of the transcripts during post-transcriptional
processing. A modest increase in MECP2_E2 transcripts
were observed in Patient 1 (Figure 3). It is possible that re-
moval of the 16nt at the end of exon 1 may remove inhibi-
tory sequences, permitting increased transcription of the E2
mRNA, which could possibly be partially compensating for
the loss of MECP2_E1, resulting in a milder RTT pheno-
type. Also, skewed X-inactivation may favor the WT allele
in Patient 1, however information on X-inactivation was
not available for this patient.
In summary, we have found a synonymous substitu-
tion in MECP2 exon 1 coding region, which results in a
splicing defect, which is predicted to lead to a truncatedprotein. We cannot, however, exclude the possibility that
other mechanisms are also involved, for instance the
possible effect on translation timing and efficiency (and
thus protein folding and function) of the switch in codon
usage at Gly16 from a high to low frequency codon [20,21],
or a contributory effect of translational competition for the
MECP2_E2 splice variant from the mutated allele. We
recommend the re-evaluation of all de novo synonym-
ous substitutions in MECP2. In particular, through in
silico analysis of all silent changes in MECP2 reported
on the Rettbase website and in the NHLBI ESP6500
exome sequence database, we found that the change
c.627G>A (p.Val209Val) increases the donor splice site
prediction score (Splice Site Prediction by Neural Network
[24]) from 0.36 to 0.91 (out of 1.0), c.948C>G (Val316Val)
changes the score from 0.09 to 0.42., and c.999G>T
(Gly333Gly) changes the score from 0 to 0.59. These three
substitutions should clearly be re-evaluated for possible
MECP2 mRNA splicing aberrations. Also, we recommend
that algorithms used in the analysis of next generation se-
quence data be updated to predict the effect on splicing
machinery at exonic sites away from the known splice
donor and acceptor sites.Additional file
Additional file 1: Table S1. In silico analysis of c.48C>T substitution for
effect on donor splice site prediction using four different algorithms [25-27].
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